-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HVFmon+vJMSMclSYDTrMRTD8cGF9tBqilXwfg8u3StshYhrZKcxWqmHdMCyFAWP/
 W1e0PGfcJNqDbwNjgtNCmg==

<SEC-DOCUMENT>0001178913-09-002263.txt : 20090924
<SEC-HEADER>0001178913-09-002263.hdr.sgml : 20090924
<ACCEPTANCE-DATETIME>20090924110046
ACCESSION NUMBER:		0001178913-09-002263
CONFORMED SUBMISSION TYPE:	SC 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20090924
DATE AS OF CHANGE:		20090924

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-50118
		FILM NUMBER:		091083967

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marathon Investments Ltd.
		CENTRAL INDEX KEY:			0001385788
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		SC 13G

	BUSINESS ADDRESS:	
		STREET 1:		1 AZRIELI CENTER, ROUND TOWER,38TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			67021
		BUSINESS PHONE:		972-3-7188700

	MAIL ADDRESS:	
		STREET 1:		1 AZRIELI CENTER, ROUND TOWER,38TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			67021
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G
<SEQUENCE>1
<FILENAME>zk97288.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\EDGAR Filing\Other Filers\Marathon Investments Ltd\Protalix Bio Therapeutics Inc\97288\a97288.eep -->
     <!-- Control Number: 97288                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Marathon Investments Ltd                                         -->
     <!-- Project Name:   SC-13G                                                           -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>SC-13G</TITLE>
</HEAD>
<BODY>

<pre>

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13G
                                 (RULE 13D-102)

        INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES
  13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

                         PROTALIX BIOTHERAPEUTICS, INC.
- --------------------------------------------------------------------------------
                                (Name of Issuer)

                     COMMON STOCK, PAR VALUE $.001 PER SHARE
- --------------------------------------------------------------------------------
                         (Title of Class of Securities)

                                    74365A101
                      -------------------------------------
                                 (CUSIP Number)

                               SEPTEMBER 24, 2009
- --------------------------------------------------------------------------------
             (Date of Event Which Requires Filing of this Statement)

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

Check the following box to designate the rule pursuant to which the Schedule is
filed:

     [_]  Rule 13d-1(b)

     [X]  Rule 13d-1(c)

     [_]  Rule 13d-1(d)

*    The remainder of this cover page shall be filled out for a reporting
     person's initial filing on this form with respect to the subject class of
     securities, and for any subsequent amendment containing information which
     would alter disclosures provided in a prior cover page.

     The information required on the remainder of this cover page shall not be
     deemed to be "filed" for the purpose of Section 18 of the Securities
     Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
     that section of the Act but shall be subject to all other provisions of the
     Act (however, see the Notes).


                                Page 1 of 5 pages
</pre>
<PAGE>
<pre>


CUSIP NO. 74365A101

- --------------------------------------------------------------------------------
1.   Name of Reporting Persons/
     I.R.S. Identification Nos. of above persons (entities only).

     Marathon Investments Ltd.
- --------------------------------------------------------------------------------
2.   Check the Appropriate Box if a Member of a Group
     (a)  [_]
     (b)  [X]
- --------------------------------------------------------------------------------
3.   SEC Use only
     [_]
- --------------------------------------------------------------------------------
4.   Place of Organization
     Israel
- --------------------------------------------------------------------------------
                   5.   Sole Voting Power
                        4,777,304
Number of          -------------------------------------------------------------
Shares             6.   Shared Voting Power
Beneficially            None
Owned by Each      -------------------------------------------------------------
Reporting          7.   Sole Dispositive Power
Person With:            4,777,304
                   -------------------------------------------------------------
                   8.   Shared Dispositive Power
                        None
- --------------------------------------------------------------------------------
9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     4,777,304
- --------------------------------------------------------------------------------
10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     [_]
- --------------------------------------------------------------------------------
11.  Percent of Class Represented by Amount in Row (9)
     6.24%
- --------------------------------------------------------------------------------
12.  Type of Reporting Person:
     IV
- --------------------------------------------------------------------------------


                                Page 2 of 5 pages
</pre>
<PAGE>
<pre>


ITEM 1.

     (A)  NAME OF ISSUER:

          Protalix BioTherapeutics, Inc. (hereinafter referred to as the
          "Issuer").

     (B)  ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

          2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100 Israel

ITEM 2.

     (A)  NAME OF PERSON FILING:

          This Statement is filed by: Marathon Investments Ltd., an investment
          company organized under the laws of the State of Israel ("Marathon").

     (B)  ADDRESS OF PRINCIPAL BUSINESS OFFICES OR, IF NONE, RESIDENCE:

          1 Azrieli Center, Round Tower, 19th Floor, 132 Menachem Begin Road,
          Tel Aviv 67021 Israel

     (C)  CITIZENSHIP:

          Place of organization of the Reporting Persons is Israel.

     (D)  TITLE OF CLASS OF SECURITIES:

          Common stock, par value $0.001 per share (the "Common Stock").

     (E)  CUSIP NUMBER:

          74365A101

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR
        240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     Not applicable.

ITEM 4. OWNERSHIP

     (a)  Amount beneficially owned: 4,777,304

     (b)  Percent of class: 6.24%

     (c)  Number of shares as to which the person has:

          (i)  Sole power to vote or to direct the vote: 4,777,304

          (ii) Shared power to vote or to direct the vote: 4,777,304

          (iii) Sole power to dispose or to direct the disposition of: NONE

          (iv) Shared power to dispose or to direct the disposition of: NONE

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than 5
percent of the class of securities, check the following [_].

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     Not applicable.


                                Page 3 of 5 pages
</pre>
<PAGE>
<pre>


ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
        SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

     Not applicable.

ITEM 10. CERTIFICATION

     By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.


                                Page 4 of 5 pages

</pre>
<PAGE>
<pre>


                                    SIGNATURE

After reasonable inquiry and to the best of our knowledge and belief, we certify
that the information set forth in this Statement is true, complete and correct.

Dated: September 24, 2009

                                   MARATHON INVESTMENTS LTD.


                                   By: /s/ Sharon Toussia-Cohen
                                   ----------------------------
                                   Sharon Toussia-Cohen,
                                   Chief Executive Officer


                                Page 5 of 5 pages
</pre>
</body>
</html>





</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
